Eli Lilly, the pharmaceutical giant, has exceeded expectations in its fourth-quarter earnings report for 2023. Their success is largely attributed to the impressive Zepbound launch of their new weight loss medication, Zepbound, and the increased sales of their well-established diabetes treatment, Mounjaro. Zepbound, approved by the FDA in November, generated $175.8 million in sales during … Read more